The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Why Do Schizophrenic Patients Refuse to Take Their Drugs?
Van Putten, T. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130049008 · Cited by 572
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
Postpsychotic Depression in Schizophrenia
McGlashan, T. H. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770020065011 · Cited by 344
Anchoring the BPRS: an aid to improved reliability.
Woerner, M. G., Mannuzza, S., & Jm, K. (1988) · PubMed · Cited by 341
Schizophrenia: A Life-shortening Disease
Allebeck, P. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.1.81 · Cited by 335
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · PubMed · Cited by 322
Seeger, T. F., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A., McLean, S., Guanowsky, V, Howard, H. R., & Lowe, J. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12023-5 · Cited by 322
Depression in first-episode schizophrenia
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1643 · Cited by 316
Mechanisms of action of atypical antipsychotic drugs
Deutch, A. Y., Moghaddam, B., Innis, R. B., Krystal, J. H., Aghajanian, G. K., Bunney, B. S., & Charney, D. S. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90030-u · Cited by 253
Minireview A systematic study of the pharmacological activities of dopamine antagonists
Niemegeers, C. J. E., & Janssen, P. A. J. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90096-1 · Cited by 232
'Revealed' Depression and Drug Treatment for Schizophrenia
Knights, A. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780320086010 · Cited by 231
Studies of Depressive Symptoms in Schizophrenia
Johnson, D. A. W. (1981) · British Journal of Psychiatry · doi:10.1192/bjp.139.2.89 · Cited by 219
Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes
Keepers, G. A. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790090075012 · Cited by 216
Neurobiological Mechanisms Involved in Antidepressant Therapies
Briley, M., & Moret, C. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199310000-00002 · Cited by 210
Medication noncompliance in schizophrenia: codification and update.
Young, J. L., Zonana, H. V., & Shepler, L. (1986) · PubMed · Cited by 198
Goff, D. C., Posever, T., Herz, L., Simmons, J., Kletti, N., Lapierre, K., Wilner, K. D., Law, C. G., & Ko, G. N. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00009 · Cited by 183
Side effect profiles of new antipsychotic agents.
Casey, D. E. (1996) · PubMed · Cited by 163
Serotonergic involvement in haloperidol-induced catalepsy.
Neal‐Beliveau, B. S., Joyce, J. N., & Lucki, I. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38100-0 · Cited by 148
Role of serotonin in the action of atypical antipsychotic drugs.
Hy, M. (1995) · PubMed · Cited by 146
Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer, M. S., Vogel, W. H., DiJohnson, C., Dewey, D. A., Sheves, P., Cavicchia, S., Little, P., Schmidt, R., & Kimes, I. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810100064012 · Cited by 144
Dopamine receptor pharmacology.
Seeman, P., & Tol, H. H. M. V. (1993) · PubMed · Cited by 134
Depressive symptoms in schizophrenia: Comprehensive differential diagnosis
Bartels, S. J., & Drake, R. E. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90062-4 · Cited by 131
Prevalence of Obesity in Patients Receiving Depot Antipsychotics
Silverstone, T., Smith, G., & Goodall, E. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.2.214 · Cited by 120
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
Newman‐Tancredi, A., Chaput, C., Verrièle, L., & Millan, M. J. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00170-0 · Cited by 114
Bench, C. J., Lammertsma, A. A., Dolan, R. J., Grasby, P. M., Warrington, S., Gunn, K. P., Cuddigan, M., Turton, D. J., Osman, S., & Frackowiak, R. S. J. (1993) · Psychopharmacology · doi:10.1007/bf02244926 · Cited by 99
Frequency and differential diagnosis of depressive syndromes in schizophrenia.
Martin, R. L., Cloninger, C. R., Guzé, S. B., & Clayton, P. J. (1985) · PubMed · Cited by 97
Depression in Chronic Schizophrenia
AGER, H., & MILSTEIN, L. N. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.7.870-c · Cited by 92
3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents
Howard, H. R., Lowe, J. A., III, Seeger, T., Seymour, P. A., Zorn, S. H., Maloney, P., Ewing, F. E., Newman, M. E., Schmidt, A. W., Furman, J. S., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950625l · Cited by 90
Bench, C. J., Lammertsma, A. A., Grasby, P. M., Dolan, R. J., Frackowiak, R. S. J., Warrington, S., Boyce, M. J., Gunn, K. P., & Brannick, L. Y. (1996) · Psychopharmacology · doi:10.1007/bf02245614 · Cited by 84
Neuroleptic Side Effects: Acute Extrapyramidal Syndromes and Tardive Dyskinesia
Casey, D. E., & Keepers, G. A. (1988) · Springer eBooks · doi:10.1007/978-3-642-73280-5_7 · Cited by 76
Negative symptoms in schizophrenia: considerations for clinical trials
Möller, H. ‐., van Praag, H. M., Aufdembrinke, B., Bailey, P., Barnes, T. R. E., Beck, J., Bentsen, H., Eich, F. X., Farrow, L. R., Fleischhacker, W. W., et al. (1994) · Psychopharmacology · doi:10.1007/bf02244775 · Cited by 71
Möller, H. ‐. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90289-x · Cited by 70
Lindenmayer, J., Grochowski, S., & Kay, S. R. (1991) · Comprehensive Psychiatry · doi:10.1016/0010-440x(91)90032-8 · Cited by 45
Janiszewski, J. S., Fouda, H. G., & Cole, R. O. (1995) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(95)00071-p · Cited by 39
FUTURE THERAPIES OF TOURETTE SYNDROME
Chappell, P. B., Scahill, L. D., & Leckman, J. F. (1997) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70324-8 · Cited by 34
The treatment of generalized anxiety disorder in patients with depressive symptomatology.
Rickels, K., & Schweizer, E. E. (1993) · PubMed · Cited by 32
The future of neuroleptic psychopharmacology.
Ortiz, A., & Gershon, S. (1986) · PubMed · Cited by 23
Depressive symptoms and schizophrenia a psychopharmacological approach.
Mc, M., Bravin, S., Fabiano, L. R. F. L. R., Vanni, S., Boscati, L., & INVERNIZZI, G. (1995) · PubMed · Cited by 15
[Adverse effects of long-term psychopharmacologic therapy on sexual functions].
Pfeiffer, W. M., Kockott, G., Fischl, B., & Schleuning, G. (1991) · PubMed · Cited by 13
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D., & Ho, B.-C. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.040 · Cited by 943
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Metadata
- Authors
- Keck Jr, P., Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, E. P., & Morrissey, M. R.
- Venue
- Psychopharmacology
- Published
- 1998-11-16
- Volume
- 140
- Issue
- 2
- Pages
- 173-184
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2061276728
- Cited by
- 265
- References
- 47
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.